Keya Medical's Three AI-Powered Products Recognized as Beijing Municipal New Technologies, New Products, and New Services

February 2022, independently developed by Keya MedicalCoronary Flow Reserve Fraction Calculation Software, Intelligent Auxiliary Diagnosis System, Non-invasive Coronary Flow Reserve Fraction Measurement ServiceThree products have been certified as “Beijing New Technologies, New Products (and Services).” This underscores Keya Medical’s industry-leading product technology and provides strong support for future market promotion.

Beijing New Technologies, New Products (Services) are jointly endorsed, professionally reviewed, and authoritatively certified by six departments: the Beijing Municipal Science & Technology Commission, the Zhongguancun Administrative Committee, the Municipal Development and Reform Commission, the Municipal Bureau of Economy and Information Technology, the Municipal Commission of Housing and Urban-Rural Development, and the Municipal Administration for Market Regulation, representing a collection of “Original Innovation, Advanced Technology, Reliable Quality, Broad Prospectshigh-standard technical product services that integrate these elements, meeting the new requirements for building a “high-end, precision, and advanced” economic structure, establishing a new development paradigm, and constructing an international science and technology innovation hub city,Benefit from preferential policy support, including government procurement and promotion and application initiatives.。

Public Notice of New Technologies, New Products (Services) in Beijing 

The three products of Keya Medical that have been certified this time are respectivelyCoronary Flow Fractional Reserve Calculation Software (DeepVessel FFR), Intelligent Auxiliary Diagnosis System (DeepVessel Analytics), and Non-invasive Coronary Flow Fractional Reserve Measurement Service.

Coronary Flow Reserve Fraction Calculation Software (DeepVessel FFR, DVFFR) isBased on Deep Learning Technologycoronary functional assessment system that enables a "one-stop" anatomical and functional evaluation of CAD, and is also the first Class III AI medical device approved by the NMPA. Currently, Keya Medical's CT-FFR product is the only one on the market that utilizes deep learning technology.Fully automated intelligent analysis for measuring fractional flow reserve,It is the only CT-FFR product recognized by the National Medical Products Administration (NMPA) as an AI-based medical device.

Non-invasive Coronary Fractional Flow Reserve (FFR) Measurement Service utilizes artificial intelligence technology to perform non-invasive FFR analysis on coronary computed tomography angiography (CTA) images, thereby accurately assessing whether patients with cardiovascular disease require coronary angiography and stent implantation.Develop Efficient Diagnosis and Treatment Plans for Patients。

The Intelligent Auxiliary Diagnosis System (DeepPulse Lingxi) is a series of smart diagnostic and therapeutic products for radiology developed by Keya Medical. Leveraging its R&D expertise in advanced AI technologies and multi-modal image analysis, and integrating the most cutting-edge clinical medical information, the system analyzes and processes clinical imaging data. It performs image reconstruction, lesion segmentation and identification, provides quantitative analytical results, and generates standardized imaging reports. The product series includes solutions for “coronary arteries,” “head and neck,” “pulmonary nodules,” “pneumonia,” “rib fractures,” “non-gated calcium scoring,” and “stroke.”

Keya Medical is firmly grounded in clinical practice, focusing on an AI-plus-medical platform in the cardiovascular field to empower the continuous upgrading of the entire specialty care process for cardiovascular diseases. Leveraging AI technology and starting with its cardiovascular disease product portfolio, Keya Medical strives to build a comprehensive AI product and service system covering the entire patient journey—from early prevention, screening, diagnosis, and treatment to disease management. This effort aims to strengthen China’s AI healthcare industry chain and enhance the diagnosis and treatment of cardiovascular diseases.

To promote the comprehensive enhancement of research and innovation capabilities in Beijing’s medical and healthcare institutions, and to participate in the high-quality development of the pharmaceutical and health industries, Keya Medical and Beijing Anzhen Hospital jointly established the “Artificial Intelligence Joint Laboratory” in August 2021. DeepVessel FFR (DVFFR) was also introduced through the “Anzhen-Keya Medical-Enterprise Joint Laboratory.”The First Innovative Project, artificial intelligence technology can be utilized to perform non-invasive FFR analysis on coronary CTA images, rapidly assessing whether borderline coronary lesions cause myocardial ischemia and guiding decisions on the need for subsequent interventional therapy. The entire examination process requires no additional contrast agent or radiation exposure, and can also reduce unnecessary invasive procedures and stent implantations.Precision Diagnosis and Treatment of Coronary Heart Disease Opens New Pathways。